Is the Indian version of Osimertinib available in pharmacies?

Osimertinib (Osimertinib) is not currently available in India. The original drug Osimertinib was originally produced and marketed by AstraZeneca Pharmaceuticals. There are also generic drugs of Osimertinib produced in other countries. The ingredients of the two drugs are basically the same, but the manufacturers are different and the prices are different. The drug osimertinib is effective at shrinking tumors in patients with these mutations, slowing the progression of the cancer, and preventing recurrence in patients with EGFR.

Osimertinib is a cancer drug called a tyrosine kinase inhibitor that blocks the activity of EGFR, which normally controls cell growth and division. In lung cancer cells, EGFR is often overactive, causing cancer cells to grow uncontrollably. By blocking EGFR, Osimertinib helps reduce the growth and spread of cancer. Available by prescription only, doctors should use genetic testing to confirm whether patients have the EGFR mutation before starting treatment. Patients should take 80 mg once a day until the disease improves or remains stable, or there is no recurrence after surgery, and the side effects are tolerable. If certain side effects occur, your doctor may decide to reduce the dose or stop treatment.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may vary. The price of the specification80mg*30 tablets per box is around 5,000 yuan, which is relatively expensive. This drug may be sold in domestic pharmacies or hospitals. The price of each box of 80mg*30 tablets produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. To purchase overseas drugs, you need to purchase them through formal channels. For more drug information, you can consult Yaode Medical Consultant.